melanoma
Sour taste for Nektar as bempegaldesleukin flunks ph3 test
Phil Taylor
Bristol-Myers Squibb, immuno-oncology, melanoma, Nektar Therapeutics, Oncology
0 Comment
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
Phil Taylor
adjuvant, HEOR, melanoma, Merck & Co, NHS, NICE
0 Comment
Merck claims another adjuvant okay from FDA for Keytruda
Phil Taylor
adjuvant, fda, Keytruda, melanoma, Merck & Co, regulatory approval
0 Comment
BioNTech takes its first cancer vaccine into phase 2
Phil Taylor
BioNTech, BNT111, cancer vaccine, immuno-oncology, melanoma, Oncology
0 Comment
IO Biotech raises $155m to develop breakthrough cancer vaccine
Richard Staines
IO Biotech, melanoma, Novo Seeds, Oncology, R&D, vaccine
0 Comment
News/ News/ News/ Oncology/ R&D
Regeneron pairs with BioNTech on melanoma immunotherapy
Phil Taylor
BioNTech, cancer vaccine, checkpoint inhibitors, immuno-oncology, Libtayo, melanoma, Regeneron
0 Comment
Market Access/ News/ News/ News/ Oncology
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Phil Taylor
Bristol-Myers Squibb, checkpoint inhibitors, immuno-oncology, melanoma, Oncology, Opdivo, Roche, Tecentriq, Yervoy
0 Comment
News/ News/ News/ Oncology/ R&D
Merck builds case for six-week Keytruda dosing as FDA starts review
Phil Taylor
immuno-oncology, Keytruda, melanoma, Merck & Co, Oncology
0 Comment